IGF-1 LR3 — 2 mg
IGF-1 LR3 (2 mg) is an engineered 83-amino-acid IGF-1 analog with reduced IGFBP binding, significantly enhanced potency, and extended biological availability. Supplied as a lyophilised research peptide for IGF-axis, cell-growth, and PK/PD investigations. For laboratory use only.
€ 39.00
Description
IGF-1 LR3 2 mg — Sterling Knight Pharmaceuticals
Brand: Sterling Knight Pharmaceuticals
Category: Injectable Peptide · IGF-1 Analog (Long R3)
Content: 2 mg IGF-1 LR3 (lyophilised)
Packaging: 1 sterile vial in carton
Origin: United Kingdom
Price: €39
Research Notice: Laboratory use only. Not for human or veterinary use.
🧬 Product Overview
IGF-1 LR3 is an engineered version of human IGF-1 that includes a
13-amino-acid N-terminal extension and an Arg→Glu (Long R3) substitution.
These modifications dramatically reduce binding to IGF-binding proteins (IGFBPs), increasing its
effective biological availability and extending its duration of action compared with native IGF-1.
With a molecular mass of ~9.1 kDa and a total length of 83 amino acids, IGF-1 LR3 is widely used in:
- Cell culture proliferation & survival assays
- IGF-1 receptor signaling studies
- PK/PD investigations across the IGF axis
- Anti-doping analytical development
🔬 Key Research Highlights
Mechanism & engineering:
Maintains IGF-1 receptor (IGF-1R) agonism while reducing IGFBP affinity, producing significantly stronger in vitro potency and prolonged bioavailability.
Protein characteristics:
Recombinant, non-glycosylated polypeptide (~9.1 kDa), 83 amino acids.
Half-life & stability:
Reported half-life ranges from 20–30 hours up to 56–72 hours, depending on system and matrix — far longer than native IGF-1.
Cell culture utility:
Supports robust proliferation and viability in serum-reduced or serum-free environments, outperforming insulin or standard IGF-1.
Sport status:
IGF-1 analogs (including LR3) are WADA S2 prohibited substances.
🧬 Mechanism of Action (Simplified)
- Agonist at IGF-1 receptor → promotes growth, survival & anabolic signaling
- Reduced IGFBP binding → increases free, active peptide concentration
- Extended half-life → prolonged receptor activation vs. native IGF-1
- Potent mitogenic and metabolic signaling actions
📊 Technical Specification Table
| Field | Data |
|---|---|
| Chemical name | Long R3 Insulin-Like Growth Factor-1 (IGF-1 LR3) |
| Chemical formula | C400H619N111O115S9 |
| Synonyms | Long R3 IGF-1 · Long Arg3 IGF-1 · LR3-IGF-I · recombinant human LR3 IGF-I |
| Molecular weight | ≈ 9,111 Da (non-glycosylated) |
| CAS number | 143045-27-6 (common listing; verify per batch COA) |
| Literature highlights |
Reduced IGFBP affinity; Stronger potency than IGF-1; Extended half-life & enhanced cell-culture performance. |
| Total active content | 2 mg per vial (lyophilised) |
| Storage / stability | Store refrigerated or as labelled; protect from light; stable ~36 months (verify COA). |
| Country of origin | United Kingdom |
📚 Research Applications
- IGF-1 signaling & mitogenic pathway research
- Proliferation & survival assays in low-serum environments
- Cell performance enhancement vs. IGF-1 or insulin
- Pharmacokinetics and IGF-axis bioavailability studies
- Anti-doping method development for growth factors
⚠️ Side Effects / Risks (Class-Based)
- Activation of IGF-1–dependent metabolic and mitogenic pathways
- Possible glucose-handling changes under certain models
- Positive anti-doping test risk under WADA S2
- Bioactive peptide: PPE and biosafety handling required
🧯 Compliance Notice
FOR RESEARCH USE ONLY.
Not for human consumption or veterinary application.
Not a dietary supplement or medicinal product.
Researchers must follow institutional biosafety SOPs and SDS guidance.
WADA Status: Prohibited under S2 — Peptide hormones, growth factors, related substances.
There are no reviews yet.
